TNBC and HER2+ BC, accounted for 37.93% (n = 51) in the nebivolol group, 35.79% (n = 180) in the carvedilol group, and 37.71% (n = 681) in the metoprolol group. The gene discussed is ERBB2; the disease is breast cancer.